Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results

EMERYVILLE, Calif., Feb. 19 OnyxPharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast ateleconference with management to provide an update on Nexavar(R) (sorafenib)tablets, as well as to discuss fourth quarter and full year 2007 financialresults, on Tuesday, February 19, 2008, at 10:00 a.m. Eastern Time (7:00 a.m.Pacific Time). Financial results for the fourth quarter and year endedDecember 31, 2007 will be released today.

Interested parties may access a live webcast of the presentation on ourwebsite at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing847-413-3238 and using the passcode 20751832. A replay of the presentationwill be available on the Onyx website or by dialing 630-652-3044 and using thepasscode 20751832 approximately one hour after the teleconference concludes.The replay will be available through March 19, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed toimproving the lives of people with cancer by changing the way cancer istreated(TM). The company, in collaboration with Bayer HealthCarePharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib)tablets, a small molecule drug. Nexavar is currently approved for thetreatment of advanced kidney cancer and for the treatment of liver cancer.Additionally, Nexavar is being investigated in several ongoing trials innon-small cell lung cancer, melanoma, breast cancer and other tumor types.For more information about Onyx, visit the company's website at:http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of BayerPharmaceuticals Corporation.

SOURCE Onyx Pharmaceuticals, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...